An editorial in the New England Journal of Medicine (NEJM) issue of 23 September 2010 took the unusual position of challenging a study published in the same issue.
Cost of new drug challenged
Home/Pharma News
|
Posted 21/01/2011
0
Post your comment

The challenge from Dr Lee Goldman and Dr Jeffrey Ginsberg in their editorial focussed around the cost of the treatment compared to the relative benefit, a growing debate in American medicine.
The study published in the NEJM proved that a blood-thinning medicine could prevent problems from worsening in some people with a sometimes painful, usually short-term and non-fatal, blood clot near the surface of the leg, called superficial-vein thrombosis.
The editorial, however, challenged the costs of the treatment (ranging from US$2,124–7,380 per patient to receive injections for 45 days) to prevent one out of 88 patients from having a more dangerous, but rarely fatal, deep vein clot.
The issue of cost-effectiveness is becoming a hot topic as more Americans become eligible for Medicare insurance, drug rebates increase and new healthcare reform aims to bring affordable health care to 30 million more people by 2019.
Healthcare expenditure in the US is already higher than any other country, and currently spends about 18% of the gross domestic product on health care.
Related article
Source: NEJM, New York Times.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment